Clinical Trials
5 trialsNCT05627245 2026-05-13
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03038672 2026-05-12
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05797233 2026-05-04
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT01695941 2026-04-13
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02911142 2025-07-28
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting